Clinical Trial Update: A Study to Assess Efficacy, Safety of KAE609 in Adult Patients With Acute Malaria Mono-infection [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the efficacy and safety of KAE609 (cipargamin) in adults with acute malaria mono-infection completed, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• KAE609 (cipargamin) (cipargamin)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Cure Rate | Phase 2 | Status: COMPLETED | Results posted: 2015-09-03